Table 1.

Patients characteristics (n = 341)

	n (%)
Gender
Female	189 (55.4)
Male	152 (44.6)
Age (years), median (range)	59 (9-89)
Age group
0-9	1 (0.3)
10-19	4 (1.2)
20-29	9 (2.6)
30-39	24 (7)
40-49	45 (13.2)
50-59	95 (27.9)
60-69	104 (30.5)
70-79	51 (15)
80-89	8 (2.3)
ECOG PS
0-1	247 (72.4)
2-4	94 (27.6)
BMI, median (range)	26 (13.6-46.4)
BMI group
<20	27 (7.9)
20-30	224 (65.7)
>30	90 (26.4)
Smoking status
Active smoker	60 (17.6)
Former smoker	70 (20.5)
Nonsmoker	202 (59.2)
Unknown	9 (2.6)
Pack-years, median (range)	25 (2-60)
Comorbidities
Without comorbidities	121 (35.5)
1 Comorbidity	42 (12.3)
2 Comorbidities	75 (22)
>2 Comorbidities	103 (30.2)
Types of comorbidities
Arterial hypertension	125 (36.7)
Ischemic cardiac disease	57 (16.7)
Diabetes mellitus	52 (15.2)
Other cardiopathy	32 (9.4)
Deep vein thrombosis and/or pulmonary embolism	32 (9.4)
Chronic obstructive pulmonary disease	28 (8.2)
Other comorbidities	28 (8.2)
Endocrinopathies	20 (5.9)
Chronic liver disease	11 (3.2)
Bacterial co-infection	10 (2.9)
Cerebrovascular disease	8 (2.3)
Peripheral arterial disease	7 (2.1)
Chronic kidney disease	6 (1.8)
Primary tumor location
Lung	66 (19.4)
Breast	60 (17.6)
Digestive	54 (15.8)
Gynecological	53 (15.5)
Hematological	25 (7.3)
Genitourinary	23 (6.7)
Skin, including melanoma	20 (5.9)
Sarcoma	11 (3.2)
Head and neck	9 (2.6)
Endocrine	9 (2.6)
Multiple primary tumors	5 (1.5)
Neuroendocrine	4 (1.2)
Central nervous system	1 (0.3)
Unknown primary tumor	1 (0.3)
Present status
Remission	37 (10.9)
Curative setting	80 (23.5)
Advanced active disease or palliation	224 (65.7)
Treatment in the previous 3 months
No	58 (17)
Yes	283 (83)
Chemotherapy	159 (46.6)
Targeted treatment	70 (20.5)
Surgery	53 (15.5)
Immunotherapy	41 (12)
Radiotherapy	34 (10)
Hormonal therapy	34 (10)

BMI, body mass index; ECOG PS, Eastern Cooperative Oncology Group Performance Status.